Table 2.
Variable | IgG (BAU/ml)* | Neutralizing (%)* | ||||
---|---|---|---|---|---|---|
Change | 95% CI | p-value | Change | 95% CI | p-value | |
Diabetic vs. Non-Diabetic | −13.86 | [−27.08 to −0.64] | 0.041 | −4.42 | [−8.53 to −0.32] | 0.036 |
Hypertensive vs. Not Hypertensive | 4.00 | [−9.95 to 17.95] | 0.575 | 0.75 | [−3.59 to 5.1] | 0.734 |
Age (per 1 year increase) | −0.43 | [−0.86 to 0] | 0.049 | −0.25 | [−0.38 to -0.12] | <0.001 |
Male vs. Female | −3.52 | [−15 to 7.96] | 0.548 | −0.31 | [−3.87 to 3.26] | 0.865 |
BMI between 25 and 30 vs. BMI < 25 | −8.70 | [−22.58 to 5.19] | 0.221 | −1.91 | [−6.29 to 2.46] | 0.392 |
BMI Greater than 30 vs. BMI < 25 | −5.76 | [−21.57 to 10.05] | 0.476 | −0.33 | [−5.3 to 4.63] | 0.895 |
Previous COVID-19 Infection vs. None | 38.50 | [23.05 to 53.96] | <0.001 | 7.11 | [2.31 to 11.91] | 0.004 |
Comorbidity score (per 1 score increase) | 4.99 | [−3.12 to 13.1] | 0.229 | 1.21 | [−1.35 to 3.77] | 0.354 |
*All models were adjusted for the variables mentioned in addition to duration since second dose of BNT162b2 (Pfizer–BioNTech) vaccine, which was modeled non-linearly with penalized splines in generalized additive models.